Aliases & Classifications for Joint Disorders

MalaCards integrated aliases for Joint Disorders:

Name: Joint Disorders 38 43
Arthropathy 73

Summaries for Joint Disorders

MedlinePlus : 43 A joint is where two or more bones come together, like the knee, hip, elbow, or shoulder. Joints can be damaged by many types of injuries or diseases, including Arthritis - inflammation of a joint. It causes pain, stiffness, and swelling. Over time, the joint can become severely damaged. Bursitis - inflammation of a fluid-filled sac that cushions the joint Dislocations - injuries that force the ends of the bones out of position Treatment of joint problems depends on the cause. If you have a sports injury, treatment often begins with the RICE (Rest, Ice, Compression, and Elevation) method to relieve pain, reduce swelling, and speed healing. Other possible treatments include pain relievers, keeping the injured area from moving, rehabilitation, and sometimes surgery. For arthritis, injuries, or other diseases, you may need joint replacement surgery to remove the damaged joint and put in a new one. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

MalaCards based summary : Joint Disorders, also known as arthropathy, is related to osteoarthritis and rheumatic disease, and has symptoms including arthralgia, back pain and metatarsalgia. An important gene associated with Joint Disorders is IL6 (Interleukin 6), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Etanercept and Hyaluronic acid have been mentioned in the context of this disorder. Affiliated tissues include bone, testes and eye, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Related Diseases for Joint Disorders

Diseases related to Joint Disorders via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 195)
# Related Disease Score Top Affiliating Genes
1 osteoarthritis 29.6 IL1B IL6 MMP3 TIMP1 TNF
2 rheumatic disease 29.4 IL1B IL1R1 TNF
3 osteomyelitis 29.0 IL1B IL1RN IL6 TNF TNFSF11
4 juvenile rheumatoid arthritis 28.7 IL1B IL1R1 IL1RN IL6 TNF
5 psoriatic arthritis 28.5 IL17A IL1B IL6 MMP3 TNF TNFSF11
6 arthritis 27.8 CSF1 IL17A IL1B IL1RN IL6 MMP3
7 rheumatoid arthritis 25.3 CSF1 IL11 IL17A IL1B IL1R1 IL1RN
8 osteoporosis 24.4 CSF1 DKK1 IL11 IL1B IL1RAPL2 IL1RN
9 scorpion envenomation 11.0 IL6 TNF
10 autoimmune inner ear disease 10.9 TIMP1 TNF
11 leukomalacia 10.9 IL6 TNF
12 angioimmunoblastic lymphadenopathy with dysproteinemia 10.9 IL6 TNF
13 diabetic foot ulcers 10.8 IL6 TIMP1
14 critical limb ischemia 10.8 IL6 TNF
15 streptococcal toxic-shock syndrome 10.7 IL6 TNF
16 lymph node disease 10.7 IL6 MMP3 TNF
17 adult respiratory distress syndrome 10.7 IL6 SERPINB2 TNF
18 transverse myelitis 10.7 IL17A IL6 TNF
19 exanthem 10.7 IL1RN IL6 TNF
20 myelitis 10.7 IL17A IL6 TNF
21 stromal keratitis 10.7 IL17A IL6 TNF
22 conjunctivochalasis 10.7 MMP3 PLAU TIMP1
23 brucellosis 10.7 IL1RN IL6 TNF
24 ileitis 10.7 IL17A IL6 TNF
25 takayasu arteritis 10.7 IL6 MMP3 TNF
26 echinococcosis 10.6 IL17A IL6 TNF
27 rheumatoid lung disease 10.6 IL17A MMP3 TNF
28 post-transplant lymphoproliferative disease 10.6 IL1R1 IL6 TNF
29 null-cell leukemia 10.6 IL6 TNF
30 recurrent corneal erosion 10.5 IL1B IL6
31 cryopyrin-associated periodic syndrome 10.5 IL1R1 IL1RN IL6
32 spondyloarthropathy 1 10.5 IL17A MMP3 TNF
33 relapsing-remitting multiple sclerosis 10.5 IL17A TIMP1 TNF
34 systemic onset juvenile idiopathic arthritis 10.5 IL1B TNF
35 multicentric reticulohistiocytosis 10.5 CSF1 TNFSF11
36 bagassosis 10.5 IL1B IL6
37 radiculopathy 10.5 IL17A IL1R1 IL6
38 kawasaki disease 10.5 IL6 MMP3 TIMP1 TNF
39 staphylococcal toxic shock syndrome 10.5 IL1B TNF
40 periodontitis, chronic 10.5 IL1B IL6 TNFSF11
41 periapical periodontitis 10.5 IL1B IL6 TNFSF11
42 laryngitis 10.5 IL1B IL6 TNF
43 osteochondritis dissecans 10.5
44 adenosine monophosphate deaminase 1 deficiency 10.5
45 crystal arthropathies 10.5
46 familial osteochondritis dissecans 10.5
47 acute vascular insufficiency of intestine 10.5 IL1B IL6 TNF
48 poems syndrome 10.5 IL1B IL6 TNF
49 mandibular cancer 10.4 CSF1 TNFSF11
50 autoimmune myocarditis 10.4 IL1B TNF

Graphical network of the top 20 diseases related to Joint Disorders:



Diseases related to Joint Disorders

Symptoms & Phenotypes for Joint Disorders

UMLS symptoms related to Joint Disorders:


arthralgia, back pain, metatarsalgia, muscle cramp, sciatica, other symptoms referable to joint, other symptoms referable to joint, shoulder region, other symptoms referable to joint, upper arm, other symptoms referable to joint, forearm, other symptoms referable to joint, hand, other symptoms referable to joint, pelvic region and thigh, other symptoms referable to joint, lower leg, other symptoms referable to joint, ankle and foot, other symptoms referable to joint, other specified sites, other symptoms referable to joint, multiple sites, joint stiffness, musculoskeletal symptom, other symptoms referable to joint, site unspecified, joint symptom, stiffness of joint, not elsewhere classified in icd10cm

GenomeRNAi Phenotypes related to Joint Disorders according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-142 9.53 CSF1 TNFSF11
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-145 9.53 TNFSF11
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-173 9.53 IL1RN
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-175 9.53 TNFSF11
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-180 9.53 CSF1 IL18R1 IL1RN PLAU TNFSF11
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-213 9.53 PLAU
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-72 9.53 IL18R1
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-75 9.53 PLAU
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-84 9.53 CSF1
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-91 9.53 CSF1 TNFSF11

MGI Mouse Phenotypes related to Joint Disorders:

46 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.3 TNFSF11 IL17A IL1RN IL18R1 IL1B CSF1
2 growth/size/body region MP:0005378 10.29 TNFSF11 TNF IL17A IL1RN IL1B CSF1
3 homeostasis/metabolism MP:0005376 10.28 TNFSF11 IL17A IL1RN CSF1 IL1B DKK1
4 immune system MP:0005387 10.25 TNFSF11 IL17A IL1RN IL18R1 IL1B CSF1
5 endocrine/exocrine gland MP:0005379 10.15 TNFSF11 TNF IL1R1 IL17A CSF1 IL6R
6 mortality/aging MP:0010768 10.13 TNFSF11 TNF DKK1 IL1R1 IL17A IL1RN
7 craniofacial MP:0005382 10.11 TNFSF11 TNF IL17A IL1B CSF1 DKK1
8 integument MP:0010771 9.97 TNFSF11 TNF IL1R1 IL1RN IL1B CSF1
9 neoplasm MP:0002006 9.81 TNFSF11 IL1B IL1R1 IL6R TIMP1 TNF
10 muscle MP:0005369 9.8 TNFSF11 TNF IL1R1 CSF1 IL6 SERPINB2
11 respiratory system MP:0005388 9.61 TNFSF11 IL17A CSF1 DKK1 IL1R1 TIMP1
12 skeleton MP:0005390 9.4 TNFSF11 IL17A IL1RN IL1B CSF1 IL1R1

Drugs & Therapeutics for Joint Disorders

Drugs for Joint Disorders (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 917)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Etanercept Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 185243-69-0
2
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 9004-61-9 53477741
3
Azithromycin Approved Phase 4,Phase 3 83905-01-5 55185 447043
4
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 53-03-2 5865
5
Thrombin Approved, Investigational Phase 4,Not Applicable
6
Bevacizumab Approved, Investigational Phase 4 216974-75-3
7
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 124-94-7 31307
8
Acetylcholine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-84-3 187
9
Acetaminophen Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 103-90-2 1983
10
Menthol Approved Phase 4,Phase 3,Phase 2,Not Applicable 2216-51-5 16666
11
Iron Approved Phase 4,Phase 1,Phase 2 7439-89-6 23925
12
Rivaroxaban Approved Phase 4,Phase 2,Phase 3,Not Applicable 366789-02-8
13
Tranexamic Acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1197-18-8 5526
14
Tranylcypromine Approved, Investigational Phase 4 155-09-9 441233
15
Celecoxib Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 169590-42-5 2662
16
Esomeprazole Approved, Investigational Phase 4,Phase 3,Phase 1 161796-78-7, 119141-88-7 4594 9579578
17
Naproxen Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 22204-53-1 1302 156391
18
Bupivacaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 2180-92-9, 38396-39-3 2474
19
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
20
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-02-2 5743
21
Ropivacaine Approved Phase 4,Phase 3,Phase 2,Not Applicable 84057-95-4 71273 175805
22
Cimetidine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 51481-61-9 2756
23
Hyoscyamine Approved Phase 4 101-31-5 64692
24
Milnacipran Approved, Investigational Phase 4 92623-85-3 65833
25
Norepinephrine Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 51-41-2 439260
26
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1959-05-2, 59-05-2 126941
27
Tacrolimus Approved, Investigational Phase 4,Phase 3 104987-11-3 445643 439492
28
Hydroxychloroquine Approved Phase 4,Phase 3,Phase 2,Not Applicable 118-42-3 3652
29
Sulfasalazine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 599-79-1 5353980 5359476
30
Leflunomide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 75706-12-6 3899
31
Adalimumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 331731-18-1 16219006
32
Infliximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 170277-31-3
33
Diclofenac Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 15307-86-5 3033
34
Etoricoxib Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 202409-33-4 123619
35
Abatacept Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 332348-12-6 10237
36
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 174722-31-7 10201696
37
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 83-43-2 6741
38
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 16590-41-3 5360515
39
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-24-8 5755
40
Certolizumab pegol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 428863-50-7
41
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 51-43-4 5816
42
Ketorolac Approved Phase 4,Phase 3,Phase 2,Not Applicable 74103-06-3, 66635-83-4 3826
43
Morphine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 57-27-2 5288826
44
Racepinephrine Approved Phase 4,Phase 3,Phase 2,Not Applicable 329-65-7 838
45
Calcium Carbonate Approved, Investigational Phase 4,Phase 3,Phase 2 471-34-1
46
Cyclophosphamide Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
47
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
48
Clonidine Approved Phase 4,Not Applicable 4205-90-7 2803
49
Pamidronate Approved Phase 4 40391-99-9 4674
50
Anastrozole Approved, Investigational Phase 4,Phase 2,Not Applicable 120511-73-1 2187

Interventional clinical trials:

(show top 50) (show all 7057)
# Name Status NCT ID Phase Drugs
1 Targeting Synovitis in Early Rheumatoid Arthritis Unknown status NCT00920478 Phase 4
2 Hyaluronan Versus NaCl 20 Ml Versus Placebo in Knee Osteoarthritis Unknown status NCT00144820 Phase 4 Injection of Hyaluronan or Saline
3 The Efficacy of Prednisone and Azithromycin in the Treatment of Patients With Cat Scratch Disease Unknown status NCT01469702 Phase 4 prednison and azithromycin;prednison, azithromycin;prednison, Azenil
4 The Effect of Biannual Monitoring With Magnetic Resonance Imaging (MRI), X-ray, or Usual Care on Treatment for Inflammatory Arthritis Unknown status NCT00808496 Phase 4
5 Subclinical Joint Bleeding in Irish Adults With Severe Haemophilia A on Personalised Prophylaxis Regimens Unknown status NCT02314325 Phase 4 ADVATE [Antihemophilic Factor (Recombinant)];ADVATE [Antihemophilic Factor (Recombinant)]
6 Birmingham Hip Resurfacing (BHR) Study: Implantation of a Hip Resurfacing Endoprosthesis Unknown status NCT00180206 Phase 4
7 Evicel Study on the Peri-operative Bleeding in Total Knee Prothesis Surgery Unknown status NCT00983112 Phase 4 Human Fibrinogen and human thrombin (Evicel);Sodium Chlorure (Physiological saline)
8 Intra-articular Bevacizumab for Recurrent Hemarthroses at Target Joints With Chronic Hemophilic Synovitis Unknown status NCT02060305 Phase 4 Bevacizumab intra-articular injection
9 Influence of Perception of Patients Suffering of Knee Osteoarthritis Regarding Effectiveness of Intra-articular Injection Unknown status NCT02835521 Phase 4 Joint injection with triamcinolone hexacetonide
10 Safety and Efficacy of Intra-articular Ozone Injections for Knee Osteoarthritis Unknown status NCT02833545 Phase 4
11 Intra-articular Botox Type A Versus Corticosteroids in Knee Osteoarthritis Unknown status NCT02829281 Phase 4 Botulinum Toxin Type A;Triamcinolone hexacetonide;Saline
12 Evaluation of the Evolution of Imaging Markers of Cartilage Degradation in Patients With Knee Osteoarthritis Receiving DROGLICAN Unknown status NCT02821468 Phase 4 Droglican;Paracetamol or oral NSAIDs excluding COX2 inhibitors
13 Assessment of a Knee Brace in Patients With Osteoarthritis Unknown status NCT02706106 Phase 4
14 Effectiveness of Trapeziometacarpal Splint Unknown status NCT02635932 Phase 4
15 Effects of Hyaluronic Acid vs. Hyaluronic Acid on Knee Osteoarthritis Unknown status NCT02625727 Phase 4
16 Intravenous Iron Sucrose in Arthroplasty Unknown status NCT02544828 Phase 4 Iron Sucrose 200mg;placebo
17 Does Intraoperative Intravenous Iron Enhance Postoperative Oxygenation Profile in Total Knee Arthroplasty Surgery? Unknown status NCT02544464 Phase 4 ferric carboxymaltose 1000 mg;placebo
18 The Post-marketing Surveillance to Evaluate the Efficacy of CHONDRON (Autologous Cultured Chondrocyte) by Arthroscopy Unknown status NCT02539069 Phase 4
19 The Post-marketing Surveillance to Evaluate the Efficacy and Safety of a CHONDRON (Autologous Cultured Chondrocyte) Unknown status NCT02539056 Phase 4
20 Multi-center Clinical Study of Guli Capsules in the Treatment of Knee Osteoarthritis Unknown status NCT02484508 Phase 4 Guli capsule;Kangguzengsheng capsule
21 Comparison of Topical and Infusion Tranexamic Acid After Total Knee Arthroplasty Unknown status NCT02453802 Phase 4 Tranexamic Acid 5%,5ml/amp;Tranexamic Acid 5%,5ml/amp;rivaroxaban (10mg);0.9% Normal Saline;0.9% Normal Saline
22 Validation of a Stress Device for the Knee Unknown status NCT02444663 Phase 4
23 Gastro-protective Effect and Pain Relief Effect of Naxozol Compared to Celecoxib in Patients With Osteoarthritis Unknown status NCT02355236 Phase 4 Naproxen/Esomeprazol 500/20mg;Celecoxib 200mg;Naxozol-Placebo;Comparator-Placebo
24 Medical Chitosan or Sodium Hyaluronate for Knee Osteoarthritis (CHOOSE) Unknown status NCT02323451 Phase 4 Sodium Hyaluronate Injection
25 Tranexamic Acid in Knee Joint Surgery Unknown status NCT02278263 Phase 4 Tranexamic Acid;Normal saline (0.9% NaCl)
26 Comparison of Floseal® and Tranexamic Acid on Bleeding Control After Total Knee Arthroplasty Unknown status NCT02152917 Phase 4 Tranexamic acid;Floseal®
27 Intraarticular Xylitol Injections for Knee Osteoarthritis Unknown status NCT02104596 Phase 4
28 Daily Activity and Gait Analysis After Viscosupplement Injection Among Hip Osteoarthritis Patients Unknown status NCT02086474 Phase 4 Hyaluronan;Bupivacaine
29 The Effect of Spironolactone on Pain in Older People With Osteoarthritis Unknown status NCT02046668 Phase 4 spironolactone
30 Outcome Comparison of Allograft and Synthetic Bone Substitute in High Tibial Osteotomy Unknown status NCT02000297 Phase 4
31 A Phase 4 Study of Imrecoxib in Treatment of Knee Osteoarthritis Unknown status NCT01985165 Phase 4 Imrecoxib
32 Comparison of Femoral Nerve Catheter and Adductor Canal Block With Steroid Adjuvant in Total Knee Replacement (TKR) Unknown status NCT01973530 Phase 4
33 Reinflation After Early Tourniquet Release in Total Knee Arthroplasty Unknown status NCT01832272 Phase 4
34 Hip Viscosupplementation: What is the Best Dosage? Unknown status NCT01810809 Phase 4 1 ampoule of Hylan GF-20;2 ampoules of Hylan GF-20;3 ampoules of Hylan GF-20
35 Bone Forming at Prosthetic Surfaces. Fingerprint2 Unknown status NCT01623687 Phase 4
36 RSA Study Using Two Types of Uncemented Acetabular Components and the Uncemented HA Coated Symax Stem Unknown status NCT01618084 Phase 4
37 Study to Evaluate the Efficacy of Milnacipran in the Treatment of Pain Due to Osteoarthritis Unknown status NCT01329406 Phase 4 Milnacipran;Placebo
38 Chondroitin Sulphate Treatment Efficacy in Rhizarthrosis. Unknown status NCT01233739 Phase 4 Chondroitin sulfate;Placebo
39 Assessment of the Effects of Chondroitin Sulphate in Patients With Knee Osteoarthritis With Functional Magnetic Resonance Imaging (fMRI) Unknown status NCT01226615 Phase 4 Chondroitin sulphate (Condrosan®);Placebo
40 Prophecy Guide Outcomes in Total Knee Replacement Surgery Unknown status NCT01163708 Phase 4
41 Close Kinect Chain Exercise With Kinesio Taping in the Management of Patellofemoral Pain Syndrome Unknown status NCT02241148 Phase 4 Acetaminophen 500mg
42 Comparison of Outcomes in Mobile and Fixed-bearing Total Knee Arthroplasty Unknown status NCT01027819 Phase 4
43 The Impact of Hyaluronic Acid Injections on Osteoarthritic Knee Mechanics Unknown status NCT00778076 Phase 4
44 Use of Cold and Compression Therapy With Total Knee Replacement Patients Unknown status NCT00712816 Phase 4
45 Trial Comparing Navigated and Conventional Implantation Techniques in Knee Replacement Surgery Unknown status NCT00431509 Phase 4
46 The Effect of Intraaricular Knee Injections of Hyaluronic Acid (HA) on Bone and Cartilaginous Debris, as a Therapeutic Indicator Unknown status NCT00422643 Phase 4 Sodium hyaluronate (hyaluronic acid)
47 Effectiveness Study of Hylan G-F 20 to Preserve Cartilage in Osteoarthritis of the Knee Unknown status NCT00393393 Phase 4 intra-articular injection of Hylan G-F 20
48 Effect of Flex-a-New on Osteoarthritis of the Knee Unknown status NCT00294801 Phase 4 flex-a-new (food supplement)
49 Comparing Clinical Outcome of 2 Different Total Knee Prostheses: Nexgen LPS-Flex Versus AGC Unknown status NCT00294528 Phase 4
50 Efficacy of Celecoxib Vs Placebo to Prevent Pain in a Paced Walk Unknown status NCT00194090 Phase 4 celecoxib

Search NIH Clinical Center for Joint Disorders

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Joint Disorders cell therapies at LifeMap Discovery.

Genetic Tests for Joint Disorders

Anatomical Context for Joint Disorders

MalaCards organs/tissues related to Joint Disorders:

41
Bone, Testes, Eye, Bone Marrow, Skin, Endothelial, Heart

Publications for Joint Disorders

Articles related to Joint Disorders:

(show top 50) (show all 121)
# Title Authors Year
1
Platelet-rich plasma for the therapeutic management of temporomandibular joint disorders: a systematic review. ( 29066000 )
2018
2
Assessment of MRI findings and clinical symptoms in patients with temporomandibular joint disorders. ( 29451403 )
2018
3
Single puncture versus standard double needle arthrocentesis for the management of temporomandibular joint disorders: A systematic review. ( 29889989 )
2018
4
Mechanical perturbation model of temporomandibular joint disorders and assessment of musculature. ( 29578945 )
2018
5
The Use of Synovial Fluid Analysis for Diagnosis of Temporomandibular Joint Disorders. ( 29861340 )
2018
6
Prevalence of tinnitus according to temporomandibular joint disorders and dental pain: The Korean National Population-based Study. ( 29314140 )
2018
7
Pediatric Temporomandibular Joint Disorders. ( 29046237 )
2018
8
Expression of chemerin in the synovial fluid of patients with temporomandibular joint disorders. ( 29331039 )
2018
9
Prevalence, Nature, and Management of Oral Stage Dysphagia in Adults With Temporomandibular Joint Disorders: Findings From an Irish Cohort. ( 29549021 )
2018
10
Evaluation of Pain Syndromes, Headache, and Temporomandibular Joint Disorders in Children. ( 29153234 )
2018
11
Management of temporomandibular joint disorders: A surgeon's perspective. ( 29574810 )
2018
12
Evaluation of a Patient With Temporomandibular Joint Disorders in Paget's Disease of Bone. ( 29361426 )
2018
13
Nonhemorrhagic joint disorders and vitamin K antagonists: an under-recognized adverse drug reaction? ( 29729202 )
2018
14
Modified SauvAc-Kapandji procedure for the distal radioulnar joint disorders of osteoarthritis and rheumatoid arthritis. ( 29551357 )
2018
15
Analysis of synovial fluid visfatin level in temporomandibular joint disorders. ( 29385907 )
2018
16
Current Concepts in the Management of Proximal Interphalangeal Joint Disorders. ( 29625647 )
2018
17
Intra-articular biomaterials-assisted delivery to treat temporomandibular joint disorders. ( 29785258 )
2018
18
Temporomandibular Joint Disorders in Older Adults. ( 29719041 )
2018
19
Comparative effectiveness of Low Level Laser therapy and Transcutaneous Electric Nerve Stimulation on Temporomandibular Joint Disorders. ( 29071032 )
2017
20
Use of Western Medicine and Traditional Korean Medicine for Joint Disorders: A Retrospective Comparative Analysis Based on Korean Nationwide Insurance Data. ( 29456569 )
2017
21
Inflammatory Joint Disorders and Neutrophilic Dermatoses: a Comprehensive Review. ( 28735350 )
2017
22
EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. ( 27697765 )
2017
23
Resveratrol, Potential Therapeutic Interest in Joint Disorders: A Critical Narrative Review. ( 28067817 )
2017
24
No evidence of association between articular status and clinical symptoms in patients with temporomandibular joint disorders. ( 28215435 )
2017
25
Quantification of cartilage oligomeric matrix protein (COMP) and a COMP neoepitope in synovial fluid of patients with different joint disorders by novel automated assays. ( 28473207 )
2017
26
The intravoxel incoherent motion MRI of lateral pterygoid muscle: a quantitative analysis in patients with temporomandibular joint disorders. ( 28332854 )
2017
27
The Role of Botulinum Toxin A in Treatment of Temporomandibular Joint Disorders: A Review. ( 29034269 )
2017
28
An Analysis of Pathological Activities of CCN Proteins in Joint Disorders: Mechanical Stretch-Mediated CCN2 Expression in Cultured Meniscus Cells. ( 27734404 )
2017
29
Regenerative Cells for the Management of Osteoarthritis and Joint Disorders: A Concise Literature Review. ( 29025215 )
2017
30
Association between composites of selected motion palpation and pain provocation tests for sacroiliac joint disorders. ( 28532864 )
2017
31
The effect of a functional appliance in the management of temporomandibular joint disorders in patients with juvenile idiopathic arthritis. ( 27716739 )
2017
32
Treatment of Temporomandibular Joint Disorders: The Unwanted Stepchild. ( 28667833 )
2017
33
Phytomedicine in Joint Disorders. ( 28275210 )
2017
34
Tinnitus in Temporomandibular Joint Disorders: Is it a Specific Somatosensory Tinnitus Subtype? ( 28452718 )
2017
35
Temporomandibular Joint Disorders as a Cause of Aural Fullness. ( 28103655 )
2017
36
The association between condylar bone changes revealed in cone beam computed tomography and clinical dysfunction index in patients with or without temporomandibular joint disorders. ( 28256415 )
2017
37
Efficacy of Temporomandibular Joint Arthrocentesis with Sodium Hyaluronate in the Management of Temporomandibular Joint Disorders: A Prospective Randomized Control Trial. ( 29038631 )
2017
38
Is There a Role for Oxidative Stress in Temporomandibular Joint Disorders? ( 29216476 )
2017
39
Correlation between skeletal Class II and temporo-mandibular joint disorders: a literature review. ( 26938175 )
2016
40
Dentists' knowledge of occlusal splint therapy for bruxism and temporomandibular joint disorders. ( 27251967 )
2016
41
Recent Tissue Engineering Advances for the Treatment of Temporomandibular Joint Disorders. ( 27704395 )
2016
42
Synovial fluid matrix metalloproteinase-2 and -9 activities in dogs suffering from joint disorders. ( 26902805 )
2016
43
Osteoblastoma of the temporal articular tubercle misdiagnosed asA a temporomandibular joint disorder. ( 28043747 )
2016
44
Atherosclerotic cardiovascular disease in patients with chronic inflammatory joint disorders. ( 26888573 )
2016
45
Balancing benefits and risks of glucocorticoids in rheumatic diseases and other inflammatory joint disorders: new insights from emerging data. An expert consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). ( 26746234 )
2016
46
Evaluation of validity and reliability of a methodology for measuring human postural attitude and its relation to temporomandibular joint disorders. ( 26768173 )
2016
47
Cerezen device provides treatment for temporomandibular joint disorders day and night. ( 27338922 )
2016
48
Temporomandibular Joint Disorders and Orofacial Pain. ( 26614951 )
2016
49
WITHDRAWN: Occlusal adjustment for treating and preventing temporomandibular joint disorders. ( 26727292 )
2016
50
Blue rubber bleb nevus syndrome with knee joint disorder. ( 27117831 )
2016

Variations for Joint Disorders

Expression for Joint Disorders

Search GEO for disease gene expression data for Joint Disorders.

Pathways for Joint Disorders

Pathways related to Joint Disorders according to GeneCards Suite gene sharing:

(show top 50) (show all 67)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.03 CSF1 IL11 IL17A IL18R1 IL1B IL1R1
2
Show member pathways
13.87 CSF1 IL11 IL17A IL18R1 IL1B IL1R1
3
Show member pathways
13.66 CSF1 IL11 IL17A IL18R1 IL1B IL1R1
4
Show member pathways
13.54 IL11 IL17A IL18R1 IL1B IL1R1 IL6
5
Show member pathways
13.36 CSF1 IL11 IL17A IL18R1 IL1B IL1R1
6
Show member pathways
13.3 CSF1 IL11 IL17A IL18R1 IL1B IL1R1
7
Show member pathways
13.21 CSF1 IL11 IL17A IL18R1 IL1B IL1R1
8
Show member pathways
12.88 IL17A IL18R1 IL1B IL6 TNF
9 12.79 CSF1 IL1B IL1R1 IL1R2 TNF
10
Show member pathways
12.76 IL1B IL1R1 IL1R2 IL6 TIMP1 TNF
11
Show member pathways
12.7 IL11 IL17A IL1B IL6 IL6R TNF
12
Show member pathways
12.65 IL17A IL18R1 IL1B IL6 TIMP1 TNF
13 12.61 IL17A IL1B IL1RN TNF TNFSF11
14
Show member pathways
12.54 IL1B IL1R1 TNF TNFSF11
15
Show member pathways
12.51 IL17A IL18R1 IL1B IL1R1 IL6 IL6R
16
Show member pathways
12.44 IL17A IL1B IL6 TNF
17 12.43 IL1R1 IL1R2 IL6 TNF
18
Show member pathways
12.39 IL17A IL1B IL6 IL6R MMP3 TNF
19
Show member pathways
12.36 CSF1 IL1B IL6 TNF
20
Show member pathways
12.33 IL1B IL1R1 IL1R2 IL1RN
21
Show member pathways
12.31 IL1B IL1R1 IL6 TNF
22 12.29 IL1R2 IL6 MMP3 PLAU
23
Show member pathways
12.27 IL18R1 IL1B IL1R1 IL1R2 IL1RN IL6
24
Show member pathways
12.25 IL11 IL1B IL1R1 IL6 TNF
25 12.24 IL1B IL1RN IL6 IL6R TNF
26
Show member pathways
12.2 IL11 IL17A IL18R1 IL1B IL1R1 IL6
27
Show member pathways
12.14 IL11 IL17A IL18R1 IL1B IL1R1 IL6
28 12.13 IL1B IL1R1 IL1R2 TNF
29 12.12 CSF1 IL1B IL1R1 TNF TNFSF11
30 12.06 IL1B IL1R1 IL6 TNF
31 12.05 CSF1 IL18R1 IL1B IL6 MMP3 TNF
32 12.04 CSF1 IL11 IL6 TNF
33 12.03 IL1B IL6 IL6R PLAU SERPINB2
34 12.01 IL17A IL1B IL6 IL6R MMP3 TIMP1
35 11.97 IL1B IL1R1 IL1R2 IL6 TNF
36 11.95 IL1B IL1R1 PLAU TNF TNFSF11
37 11.91 IL6 IL6R TIMP1
38 11.91 IL1B IL6 TNF
39
Show member pathways
11.91 MMP3 TIMP1 TNF
40
Show member pathways
11.9 IL6 IL6R TIMP1 TNFSF11
41
Show member pathways
11.88 IL17A IL6 IL6R
42 11.87 IL17A IL1B IL1R1 TNF
43 11.83 CSF1 IL1B IL6 TNF
44 11.78 IL1B IL6 TNF
45 11.76 IL1B IL6 PLAU TIMP1 TNF
46
Show member pathways
11.75 IL1B IL6 MMP3 TNF
47